MAY 18, 2017: A strategic weapon in the fight against recalcitrant cancers.

According to the American Cancer Society’s Cancer Facts & Figures 2017,  there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US this year.

This is horrible news that can’t be sugar coated.  Everyone’s life has been impacted by cancer and will continue to be.

But if we take a peek at the micro-trends, we can clearly see progress.  According to the ACS, cancer peaked at 215 deaths per 100,000 persons in 1991. As of 2014, that rate had dropped to 161 per 100,000 (a decline of 25%), primarily because of reductions in smoking and improvements in early detection and treatment.

This decline translates into more than 2.1 million fewer cancer deaths over the past two decades – progress that is driven by rapid declines in death rates for the four most common cancer types – lung, colorectal, breast, and prostate.

At Certis Oncology Solutions, we would like to dedicate our first blog post to the people worldwide who are committed to continuing to reverse the trend and turn horrible news into better news.  Some of them work for our company here in Southern California.

Here is a little about us:

Certis Oncology is a specialized medical oncology diagnostic and translational science company.  Every patient’s cancer is different, so our mission is to enable physicians to personalize their current therapy for patients suffering from recalcitrant cancers.

Our process is called PDOX: Patient Derived Orthotopic Xenografts. We have found that surgical implantation of the patient’s tumor in the corresponding location in the mouse – the orthotopic or correct location – provides the closest tumor behavior to the patient. 

This process enables the concurrent testing of multiple drugs in multiple mice against metastasis, which is the lethal aspect of cancers, as well as against the primary tumor.  The studies show that this increases the accuracy, effectiveness and timeliness of treatment of the patient’s cancer.  In short, PDOX is the most clinically relevant mouse cancer model. And any drug can be tested on any PDOX tumor type.

Our team comprises leading oncologists, physicians and scientists from UCLA and UCSD.

We employ PDOX technology to provide pre-clinical research to Pharma and Biotech companies to evaluate the effectiveness of their new drugs. Certis Oncology has been providing this type of service for decades and has been awarded more than 600 contracts. 

Certis Oncology will debut at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2.  We’ll be in booth #6026. 

Please drop by to learn how we’re planning to continue to reverse the trend.


Comments are closed.